10
staff
Jessica Marshall
Jessica Marshall is an associate at FasterCures.
report
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical i
nnovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not think possible.
+ Read More
report
The Promise of Multi-Cancer Early Detection Technologies in Encouraging Research and Development
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering 
;the market and can identify multiple cancers early and simultaneously.
+ Read More
report
Policy Issue Brief: A Call to Action for Diversity in Clinical Trials
FasterCures has initiated a body of work to advance system change within biomedical research to foc
us on and value diversity and representation within clinical trials.
+ Read More
report
A Global Early Warning System for Pandemics: A Blueprint for Coordination
The COVID-19 pandemic has had enormous health, social, and economic consequences.
report
Landscape of Trust: Health Data Frameworks
The rapid advancement of the health technology landscape relies heavily on patient data.
report
Models for Financing Antibiotic Development to Address Antimicrobial Resistance
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to id
article
Milken Institute Outlines Next Steps for Mobilizing an Early Warning System for Pandemics
Washington, DC, March 30, 2022—Recognizing the most effective way to combat the next pandemic is to
start planning for it now, FasterCures, a center of the Milken Institute, released key considerations and next steps for mobilizing an e
+ Read More
article
Milken Institute statement on ARPA-H inclusion in FY2022 spending bill
Esther Krofah
Executive Director
Milken Institute FasterCures and Center for Public Health
article
FasterCures Statement of Support for 21st Century Cures 2.0 Legislation
FasterCures, a center of the Milken Institute, has long supported policies that accelerate new, cutt
ing-edge biomedical innovations to patients.
+ Read More